Female Contraceptive Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Female Contraceptive Market is segmented By Contraceptive Drugs (Oral Contraceptives, Topical Contraceptives, Contraceptive Injectables, Other Contraceptive Drugs), By Devices, and Geography.

Market Snapshot

female contraceptives market
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 8.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Female Contraceptive Market is expected to register a CAGR of 8.5% during the forecast period. The major factors propelling the growth of the market include the increasing incidence of the STD, an increasing rate of unintended pregnancies, and the rise in government initiatives.

It has been observed that teenage pregnancy numbers are the highest in Western Europe. Preventing teen pregnancy is generally significant among policymakers and the public because of its high economic, social, and health costs for parents and their families. In Europe, Britain has the highest number of abortions and a majority of this is contributed by teenagers. Thus, government initiatives are also promoting the use of contraceptives to avoid unnecessary births.

Furthermore, according to the World Fertility and Family Planning 2020 report, estimates that currently, contraceptive use ranges from around 60% in Latin America and the Caribbean, Eastern and South-Eastern Asia, Europe and Northern America, and Australia and New Zealand, to under 50% in Central and Southern Asia (44.8%), Northern Africa and Western Asia (35.1%), sub-Saharan Africa (34.1%) and Oceania (30.7%). Hence, owing to above factors, it is expected that there will be an increase in the demand for female contraceptive products, which will ultimately drive the market.

Scope of the Report

As per the scope of the report, contraceptive drugs and devices are the drugs and devices used for birth control. Contraception is more commonly known as fertility and birth control is described as the method used to avoid pregnancy. These devices and drugs function by changing the mechanism of ovulation or by acting as a physical barrier between the sperm and ovum. The female contraceptive market is segmented by contraceptive drugs, devices, and geography.

By Contraceptive Drugs
Oral Contraceptives
Combined Oral Contraceptive Pill
Other Oral Contraceptive Drugs
Contraceptive Injections
Topical Contraceptives
By Device
Female Condoms
Diaphragms and Caps
Vaginal Rings
Contraceptive Sponges
Sub-dermal Contraceptive Implants
Intra Uterine Contraceptive Devices (IUCDs)
Copper IUCDs
Hormonal IUCDs
Other Devices
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Oral Contraceptives Segment is Expected to Hold a Major Market Share in the Female Contraceptive Market

Oral contraceptive pills are seen as the easiest method of contraception in the industry. They act by prohibiting implantation within the uterus if taken within 2-3 days of having unsafe sexual contact. The simplicity of their usage makes them an ideal contraceptive in the market. These are easily marketed across large regions by global companies and thus easily consumed by a large section of the population, globally. These factors are expected to contribute to the growth of the market over the forecast period. The other forms of contraceptive drugs, such as topical and injectable contraceptives have also witnessed a strong market demand. 

Furthermore, according to the World Fertility and Family Planning 2020 report, globally in 2019, about 49% of all women in the reproductive age range (15-49 years) were using some form of contraception compared to 42% in 1990. Thus, owing to the above factors the segment is expected to show growth over the forecast period.

Female key trend 3.png

North America has been Reported with the Largest Share and Consistent Growth over the Forecast Period.

North America is expected to register high growth, owing to the presence of sophisticated healthcare infrastructure, the high adoption rate of contraceptive drugs, and the rising number of government initiatives that help in increasing the overall market. A large section of the women population represents the reproductive age in the United States as well as Canada. With that, a significant size of the population is at risk of unintended pregnancy, as their partners do not use a contraceptive method, correctly and consistently. The awareness regarding these products is also high with considerable support being provided by several hospitals to control the patients affected by its misuse. 

As per the Centers for Disease Control and Prevention (CDC), in 2018, it was estimated that about 3,791,712 babies were born in the United States, with a birth rate of 11.6 per 1,000 population. Moreover, the distribution channel of several companies is well established across the United States and Canada, which overall drives the market and contributes to the largest share, over the forecast period.

Female Contraceptive Market2

Competitive Landscape

The Female Contraceptive Market is fragmented competitive and several global, as well as local players, are involved in this market. As the concern of unwanted pregnancy is rising in various countries across the globe, there is a great opportunity for companies to grab the significant market share. In the near future, it is expected that new companies will be entering the market with cost-effective drugs or devices and these companies may pose a strong competition to the current market players.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Incidence of the STDs

      2. 4.2.2 Increasing Rate of Unintended Pregnancies

      3. 4.2.3 Rise in Government Initiatives

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Devices and Treatment

      2. 4.3.2 Side Effects Associated with the Use of Contraceptive Drugs and Devices

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Contraceptive Drugs

      1. 5.1.1 Oral Contraceptives

        1. Combined Oral Contraceptive Pill

        2. Other Oral Contraceptive Drugs

      2. 5.1.2 Contraceptive Injections

      3. 5.1.3 Topical Contraceptives

      4. 5.1.4 Spermicides

    2. 5.2 By Device

      1. 5.2.1 Female Condoms

      2. 5.2.2 Diaphragms and Caps

      3. 5.2.3 Vaginal Rings

      4. 5.2.4 Contraceptive Sponges

      5. 5.2.5 Sub-dermal Contraceptive Implants

      6. 5.2.6 Intra Uterine Contraceptive Devices (IUCDs)

        1. Copper IUCDs

        2. Hormonal IUCDs

      7. 5.2.7 Other Devices

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Bayer AG

      2. 6.1.2 Mayer Laboratories Inc.

      3. 6.1.3 Pfizer Inc.

      4. 6.1.4 Mylan Pharmaceuticals Inc.

      5. 6.1.5 Teva Pharmaceuticals

      6. 6.1.6 Merck & Co.

      7. 6.1.7 Agile Therapeutics

      8. 6.1.8 Lupin Pharmaceuticals Ltd

      9. 6.1.9 The Female Health Company

      10. 6.1.10 Fuji Latex Co. Ltd

      11. 6.1.11 Johnson and Johnson

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Female Contraceptive Market market is studied from 2018 - 2026.

The Female Contraceptive Market is growing at a CAGR of 8.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Bayer AG, Pfizer Inc, Merck & Co., Inc, Teva Pharmaceuticals, Agile Therapeutics are the major companies operating in Female Contraceptive Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!